Author: David Boyer (United States)
Co-authors:
Purpose
Age-related macular degeneration (AMD) is characterized by progressive mitochondrial dysfunction in retinal pigment epithelial cells, resulting in higher reactive oxygen species (ROS) levels and leading to apoptosis. Elamipretide binds to cardiolipin to stabilize mitochondrial structure and reduce ROS emission, thereby slowing and reversing effects of oxidative stress.
Setting/Venue
The ReCLAIM program consists of two clinical trials to evaluate the safety and efficacy of elamipretide for the treatment of noncentral geographic atrophy (NCGA) secondary to age-related macular degeneration (AMD). ReCLAIM-1 was performed at a single center in the US; ReCLAIM-2 is ongoing at 42 locations in the US.
Methods
ReCLAIM-1 was an open-label, Phase I trial in which dry AMD patients with non-central geographic atrophy (NCGA) or high-risk drusen were treated with 40 mg subcutaneous elamipretide daily for 24 weeks. Safety and visual function were assessed from baseline to week 24. Outcomes were assessed separately in pre-defined NCGA and high-risk drusen (HRD) subgroups, and the NCGA results are presented here. Best corrected visual acuity (BCVA) and low-luminance visual acuity (LLVA) were assessed. Area of NCGA was measured by fundus autofluorescence (FAF). ReCLAIM-2 is an ongoing, randomized, placebo-controlled Phase-2 trial of subcutaneous elamipretide for treatment of NCGA. Patients are being randomized 2:1 to receive subcutaneous elamipretide (40 mg daily) or placebo for 48 weeks, with a primary endpoint of LLVA at 48 weeks. BCVA and low-luminance reading visual acuity (LLVA) as well as change in GA area measured by FAF and OCT will also be assessed.
Results
In ReCLAIM-1, subcutaneous elamipretide was well tolerated. Injection site reactions were observed; however, there were no serious ocular or non-ocular safety concerns. Mean distance BCVA and LLVA in the NCGA subgroup (n = 19) improved significantly at week 24 compared to baseline (4.6 ± 5.1 and 5.4 ± 7.9 letters, respectively; P < 0.05). At week 24, LLVA improved > 5 letters in 53.3% of patients, > 10 letters in 33.3%, and > 15 letters in 6.7%. Using the square root area of NCGA, the mean (SD) at baseline was 1.690 (0.9773) mm2 by FAF, increasing by 0.136 (0.0831) mm2 at week 24 (P < 0.05). These results led to the initiation of ReCLAIM-2 (N = 180) in which the primary endpoint is mean change in LLVA. Mean baseline age (SD) for all patients is 77.0 (8.5) years, and 61.2% (n = 101) are female. Entering mean (SD) BCVA and LLVA are 76.0 (8.7) letters and 55.0 (14.6) letters, respectively. Mean (SD) baseline NCGA area on FAF is 2.7 (2.5) mm2. The trial is currently underway.
Conlusions
Subcutaneous elamipretide appeared safe in the ReCLAIM-1 trial. BCVA and LLVA in NCGA patients improved significantly at 24 weeks. Mean NCGA growth at 24 weeks appeared reduced compared to natural history studies, and further investigation is ongoing in the ReCLAIM-2 study.
Financial Disclosure
Consultant for: NGMB Biopharma, Apellis Pharmaceuticals, Boehringer-Ingelheim Pharmaceuticals, Genentech, Roche, Galimedix Therapeutics, Oxurion, Palatin Technologies, Inc., Iveric bio
Comments
-